FabRx
FabRx is a specialist biotech company developing 3D printing technology for fabricating personalized pharmaceuticals and medical devices.
- CEO / Founder
- Álvaro Goyanes
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $825K
- Latest Round
- Grant
- Key Investors
- Innovate UK (non-dilutive)
Technology & Products
Key Products
FabRx provides pharmaceutical 3D printers, software, and pharma-ink development services for personalized medicine and small batch manufacturing. Their offerings include compounding technology and pharmacy automation solutions.
Technological Advantage
Proprietary formulations enabling controlled drug release; bootstrapped to £1M+ revenue without VC funding
Differentiation
Value Proposition
Enables personalized medicine through 3D printed pills with customized dosages and drug release profiles.
How They Differentiate
Only commercially available 3D printer with pharmaceutical-grade certification and hospital deployment
Market & Competition
Target Customers
Hospitals, pharmacies, pharmaceutical companies, research institutions
Industry Verticals
Pharmaceuticals, Healthcare, Personalized Medicine
Competitors
Aprecia (Spritam), Laxxon Medical, MERCK
Growth & Milestones
Growth Metrics
$1M estimated revenue; 46 employees as of 2024; Bootstrapped + non-dilutive funding to date; First external funding round planned for end of 2025
Major Milestones
2014: Founded as UCL spinout; 2019: Won £650K Innovate UK grant with Katjes Fassin; 2020: Launched M3DIMAKER flagship 3D printer; 2024: Expanded to 46 employees; 2025: Planning first external funding round
Notable Customers
Hospitals for personalized medicine, Compounding pharmacies, Research labs globally, Katjes Fassin (joint Innovate UK project)